logo-loader
viewTesla Inc

FBI looking into Tesla’s Model 3 productions numbers, says WSJ

Federal agents are reportedly reviewing Model 3 production numbers as part of a criminal investigation

Tesla charger
Tesla confirmed that it received a voluntary request for documents about its public guidance

The US Federal Bureau of Investigations is taking a look into Tesla Inc’s (NASDAQ:TSLA) Model 3 production numbers, according to a Wall Street Journal report published Friday.

Federal agents are allegedly reviewing Model 3 production numbers dating back to early 2017 as part of a criminal investigation, as per the report.

READ: Tesla beats the Street and delivers; posts profit and ramps up Model 3 production

Tesla released a statement in response, confirming that it received a voluntary request for documents about its public guidance for the Model 3 and had cooperated.

“Tesla's philosophy has always been to set truthful targets – not sandbagged targets that we would definitely exceed and not unrealistic targets that we could never meet. While Tesla gets criticized when it is delayed in reaching a goal, it should not be forgotten that Tesla has achieved many goals that were doubted by most,” stated Tesla.

The company said it has not received a subpoena, a request for testimony or additional documents, or any other formal process from the Department of Justice.

Shares of Tesla were unfazed, up more than 4% to US$327.61 in Friday afternoon trading.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

Quick facts: Tesla Inc

Price: 349.88 USD

NASDAQ:TSLA
Market: NASDAQ
Market Cap: $63.07 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

45 minutes ago

2 min read